Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.

FRANK SULLIVAN

Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.

FRANK SULLIVAN

Medicine

Research output: Chapter in Book or Conference Publication/Proceeding › Conference Publication › peer-review

Original language	English (Ireland)
Title of host publication	48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Place of Publication	Chicago, IL, USA
Publication status	Published - 1 Jun 2012

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Glynn, SA,Toner, A,Lewis, J,Sullivan, F,Breen, L,Clynes, M,Giles, FJ

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@inproceedings{dfb04552d97947599890e2a263357549,

title = "Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.",

author = "FRANK SULLIVAN",

year = "2012",

month = jun,

day = "1",

language = "English (Ireland)",

booktitle = "48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)",

}

Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro. / SULLIVAN, FRANK.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, USA, 2012.

Research output: Chapter in Book or Conference Publication/Proceeding › Conference Publication › peer-review